In this issue:
Vedolizumab for chronic pouchitis
Onset of effect of biologics and small molecules in moderate–severe UC
Guselkumab and/or golimumab in UC
Increasing adalimumab dose interval for CD in stable remission
5-ASA maintenance not superior to no maintenance in newly diagnosed CD
Psychological intervention improves work productivity and daily activity in CD
Impact of malnutrition and nutritional support in hospitalised IBD patients
Vedolizumab vs. ustekinumab in anti-TNF-experienced CD
Early biologics in operated CD reduces endoscopic recurrence
Early response after tofacitinib initiation in UC
Please login below to download this issue (PDF)